{
    "nctId": "NCT01049425",
    "briefTitle": "Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer",
    "officialTitle": "Randomised Comparison of Adjuvant Docetaxel / Cyclophosphamide With Sequential Adjuvant EC / Docetaxel Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Primary Breast Cancer, Her2 Non-overexpressing",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 3198,
    "primaryOutcomeMeasure": "disease-free survival in patients treated with either 6 cycles of Docetaxel / Cyclophosphamide chemotherapy or 4 cycles of EC followed by 4 cycles of Docetaxel as adjuvant treatment",
    "eligibilityCriteria": "Inclusion Criteria(Screening):\n\n* Female patients, age at diagnosis 18 - 75 years\n* Histological confirmed unilateral primary invasive carcinoma of the breast\n* Adequate surgical treatment with complete resection of the tumor (R0) and resection of \\> or = 10 axillary nodes or SLN in clinically N0 patients\n* T1 - T4 (if operable, inflammatory breast cancer is excluded)\n* Her-2 non-over expressing tumor confirmed by IHC/FISH\n* Estrogen and/or progesterone receptor analysis performed on the primary tumor prior to randomization. Results must be known at the time of randomization\n* Node positive disease or node negative disease with at least one other risk factor (tumor size \\> or = 2 cm, grade \\> or = 2, ER and PR negative, high uPA//PAI-1 levels)\n* No evidence for distant metastasis (M0) after conventional staging\n* Performance Status ECOG \\< or = 1 or KI \\> or = 80 %\n* The patient must be accessible for treatment and follow-up\n* Written informed consent for central pathology review and evaluation of Recurrence Score (HR positive) and participation in the planB trial prior to beginning specific protocol procedures\n\nHR positive patients:\n\n* Patient willingness to participate in adjuvant chemotherapy planB trial if RS \\> 11\n* Indication for chemotherapy given provided either \\> 4 involved lymph nodes or RS \\> 11 in 1-3 lymph nodes or N0 disease\n\nAdditional Inclusion Criteria (Randomisation to chemotherapy):\n\n* Laboratory requirements (within 21 days prior to randomization):\n\n  * Leucocytes \\> or = 3.5 109/L\n  * platelets \\> or = 100 109/L\n  * haemoglobin \\> or = 10 g/dL\n  * total bilirubin \\< or = 1 ULN\n  * ASAT (SGOT) and ALAT (SGPT) \\< or = 2.5 UNL\n  * creatinine \\< 175 ymol/L (2 mg/dL)\n* Negative pregnancy test (urine or serum) within 7 days prior to randomization in premenopausal patients\n* LVEF within normal limits of each institution measured by echocardiography or MUGA scan and\n\nExclusion Criteria(Screening):\n\n* HER2 over expression confirmed by IHC/FISH/CISH\n* Known hypersensitivity reaction to the compounds or incorporated substances\n* Known polyneuropathy \\> or = grade 2\n* Severe and relevant comorbidity that would interact with the application of cytotoxic agents or the participation in the study including acute cystitis and ischuria and chronic kidney disease.\n* Prior malignancy with a disease-free survival of \\< 10 years, except curatively treated basalioma of the skin, pTis of the cervix uteri or ipsilateral ductal carcinoma in-situ (DCISpTis of the breast)\n* Non-operable breast cancer including inflammatory breast cancer\n* Previous or concurrent treatment with cytotoxic agents for any reason after consultation with the sponsor\n* Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry\n* Male breast cancer\n* Concurrent pregnancy; patients of childbearing potential must implement a highly effective (less then 1% failure rate) non-hormonal contraceptive measures during the study treatment\n* Breast feeding woman\n* Sequential breast cancer\n* Lack of patient compliance\n\nAdditional Exclusion Criteria (Randomisation):\n\n* Inadequate organ function including:\n\n  * Leucocytes \\< 3,5 G/l\n  * platelets \\< 100 G/l\n  * creatinine or bilirubin above normal limits\n  * alkaline phosphatise \\> 5 UNL\n  * ASAT and/or ALAT associated with AP \\> 2.5 UNL\n  * uncompensated cardiac function\n* Time since axillary dissection \\> 42 days",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}